Awaiting Dengue Hemorrhagic Fever Prevention Vaccines

Indonesia is the second country in the world with the highest number of dengue cases. Not surprisingly, the presence of dengue fever vaccine (DHF) is needed to prevent and control the number of cases that occur.

After being introduced several years ago, the DHF vaccine has finally been able to be used by the people of Indonesia. Since September 2016, BPOM has formalized the use of DHF vaccine for the prevention and control of dengue fever.
Endemic Dengue Fever

DHF is caused by the bite of a mosquito infected with one of four types of dengue virus. This disease is characterized by high fever which appears three days to two weeks after a bite. About 75% of the world's population most at risk of contracting this disease live in countries in Southeast Asia and Asia-Pacific.

In 2013, the DHF morbidity rate in India was 41.25 per 100,000 population. In more severe conditions, DHF requires intensive care in a hospital and can even result in death. In 2013, the fatality rate of dengue cases in Indonesia was 0.7% of the total number of patients.
Development of DHF vaccine

Dengue fever vaccine began to develop since the 1940s and only developed rapidly in the last decade.
As a general rule, vaccines can only be used officially after several years of testing through four stages: a preclinical step and three stages of clinical trials to prove their effectiveness and safety. The new vaccine was declared to have passed the test and obtained certification after proving that it was effective enough to prevent DH and did not pose a risk to patients at risk.

One of the most common types of dengue vaccine is a weakened dengue virus. This vaccine contains an attenuated virus which is useful for awakening human immunity without causing disease.

Remember that four types of viruses can cause DHF (DEN1, DEN 2, DEN 3 and DEN 4). So you need a vaccine that can effectively prevent all four types of infections, also known as tetravalent vaccines. DHF vaccine, which is now circulating in Indonesia, has entered the third phase of clinical trials and is well known for being immunized against these four types of viruses.

Based on the latest research, this dengue vaccine can significantly reduce the risk of hospitalization and the risk of severe dengue fever, especially in children over 9 years. For safety level, it has been proven that dengue vaccine is good and there are no serious side effects for vaccine users.

Although dengue vaccine is now available, this does not mean that the DHF vaccine is the only way to prevent someone from contracting dengue. It is best to continue to take actions to prevent DH, such as avoiding mosquito bites and keeping the environment clean.

0 Response to "Awaiting Dengue Hemorrhagic Fever Prevention Vaccines"

Post a Comment

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel